Accepts insurance
Listing updated Oct 2, 2026
Le Ami Medical Spa Englewood NJ
Le Ami Medical Spa Englewood NJ · 22 Engle Street · Englewood, NJ 07631
5.0· 24 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
About this practice
Le Ami Medical Spa Englewood NJ is a medical spa in Englewood, New Jersey, whose listing shows weight-loss care including semaglutide, IV therapy and aesthetic services. Its website currently says a new site is being built. On Google it has a 5.0-star rating across 24 reviews dating back to 2023, though none have been posted in the past year; reviewers most often mention the staff and the providers' knowledge, and 6 mention results.
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | Yes |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 5.0
Google rating · 24 reviews
1
reviews mention weight loss
Counts computed by RetaMaps from public Google reviews; most recent review 2024-08-16. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 24 Google reviews. Of the 21 reviews we analyzed, 21 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Friendly, helpful staff8 reviews
- Weight-loss results6 reviews
- Knowledgeable, professional providers6 reviews
- Clean, comfortable office4 reviews
Common complaints
No negative reviews among those we analyzed.
5★
21
4★
0
3★
0
2★
0
1★
0
Most recent Google reviews
Stacey P.★★★★★2024-04-17Erika and Faye are amazing. I have been to the spa with my girls and by myself for amazing facials and hosted a botox party which I highly recommend doing!! They were great and everyone was very happy with the outcome!!
Tara A.★★★★★2024-04-15This was by far the best results I have had with Botox. Erica really listened to my issues that occurred from having Botox in the past. She understood my concerns because my results were perfect! Thank you Erica! I won’t be going to anyone else!
Susan L.★★★★★2024-01-03I just had the best Glo facial with dermaplanning by Fay! It was very relaxing and my skin is beyond radiant and so smooth💜
Avery M.★★★★★2024-01-03I saw Erika today for a lip flip and filler and it came out amazing, it looks so natural! I was so nervous but she was so kind and patient. She made me feel comfortable throughout my entire appointment. I definitely recommend Le Ami Med Spa!!
Lorri A.★★★★★2023-12-14Great hydro facial! Thank you.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Nearby providers in Englewood
Accepts insuranceSemaglutide todayTirzepatide today
Listing updated Oct 2, 2026
Garden State Diet
493 Engle Street · Englewood, NJ 07631
Accepts insuranceCash pay
Listing updated Oct 2, 2026
Accepts insurance
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs